Halozyme Therapeutics 2010 net loss decreases to $53.2 million

[News]

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

More... (http://www.news-medical.net/news/20110311/Halozyme-Therapeutics-2010-net-loss-decreases-to-24532-million.aspx)